Advanced search
Publication Cover
Hematology Volume 12, 2007 - Issue 6
Submit an article Journal homepage
188
Views
6
CrossRef citations to date
0
Altmetric
Articles

Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea

V. TutaevaNational Hematology Research Centre, Novui Zukovskii pr 4A 125167 Moscow, Russia
,
A. V. MisurinNational Hematology Research Centre, Novui Zukovskii pr 4A 125167 Moscow, Russia
,
J. J. MichielsGoodheart Institute and Foundation HematologyHemostasis and Thrombosis Science Center, Rotterdam, The Netherlands
,
J. M. RozenbergNational Hematology Research Centre, Novui Zukovskii pr 4A 125167 Moscow, Russia
,
M. A. SokolovaNational Hematology Research Centre, Novui Zukovskii pr 4A 125167 Moscow, Russia
,
V. L. IvanovaS.P. Botkin Hospital, 2-i Botkinskii pr d5 Moscow, Russia
,
T. I. KolosheinovaNational Hematology Research Centre, Novui Zukovskii pr 4A 125167 Moscow, Russia
,
T. E. ManakovaNational Hematology Research Centre, Novui Zukovskii pr 4A 125167 Moscow, Russia
,
A. A. LevinaNational Hematology Research Centre, Novui Zukovskii pr 4A 125167 Moscow, Russia
,
E. A. SemenovaNational Hematology Research Centre, Novui Zukovskii pr 4A 125167 Moscow, Russia
&
N. D. KhoroshkoNational Hematology Research Centre, Novui Zukovskii pr 4A 125167 Moscow, Russia
 show all
Pages 473-479 | Published online: 04 Sep 2013

References

  • Zandian KH. Physical growth parameters in thalassemic children in Ahwaz-Iran. Iranian J Thalassemia 1998;13:42–45.
  • Behrman RE, Kliegman RM, Homozygous HB. Nelson textbook of pediatrics. 17th ed. Philadelphia: WB Sauders Co. 2004. p 1484–1487.
  • Carusu Nicoletti M, De Sanctis V, Capra M, et al. Short stature and body proportion in thalassemia. J Pediatr Endocrinol Metab 1998;11:811–816.
  • Fuchs G, Tienboorn P, Khalad M, et al. Nutritional support and growth in thalassemia major. Arch Dis Child 1997;76: 509–512.
  • Cavello L, Gurrado R, Gallo F. Growth deficiency in polytransfused beta-thalassemia patients is not growth hormone dependent. Clin Endocrinol Oxf 1997;46:701–706.
  • George A, Bhadruri A, Sen S, et al. Physical growth parameters in thalassemic children. Indian J Pediatri 1997;64:861–871.

References

  • Spivak JL. Diagnosis of the myeloproliferative disorders: Resolving phenotypic mimicry. Semin Hematol 2003;40(1 Suppl 1):1–5.
  • Spivak JL. The chronic myeloproliferative disorders: Clonality and clinical heterogeneity. Semin Hematol 2004; 41(2 Suppl 3):1–5.
  • Klippel S, Strunck E, Busse CE, Behringer D, Pahl HL. Biochemical characterization of PRV-1, a novel hematopoietic cell surface receptor, which is overexpressed in polycythemia rubra vera. Blood 2002;100(7):2441–2448, October 1.
  • Kralovics R, Buser AS, Teo SS, Coers J, Tichelli A, van der Maas AP, Skoda RC. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 2003;102(5): 1869–1871, Sepetember 1; Epub 2003 May 1.
  • Pahl HL. PRV-1 mRNA expression and other molecular markers in polycythemia rubra vera. Curr Hematol Rep 2003; 2(3):231–236.
  • Pahl HL. Current evaluation of the clinical, diagnostic, and therapeutic usefulness of pry-1 and c-mpl markers in polycythemia vera and essential thrombocythemia. Chin Adv Hematol Oncol 2004;2(4):202–204.
  • Kralovics R, Skoda RC. Molecular pathogenesis of Philadel-phia chromosome negative myeloproliferative disorders. Blood Rev 2005;19(1):1–13, January.
  • WHO of the chronic myeloproliferative diseases (CMPD). Polycythemia vera, chronic idiopathic myelofibrosis, essential thrombocythemia and CMPD unclassifiable. WHO classifi-cation of tumours Tumours of haemtopoiesis and lymphoid tissues. Lyon: IARC; 2001.
  • Michiels JJ, De Raeve H, Berneman Z, Van bockstaele D, Hebeda K, Lam K, Schroyens W. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification and staging of Philadelphia-chromosome-negative myeloproliferative dis-orders. Semin Thromb Hemost 2006;32:307–340.
  • Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate—phenol—chloro-form extraction. Anal Biochem 1987;162(1):156–159.
  • Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Cancer genome project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365 (9464):1054–1061, March Erra-tum in: Lancet. 2005 July 9–15;366(9480):122.
  • Fröhli P, Graf C, Rhyner K. Die prophylaxe vascularer komplikationen bei polycythemia vera und primarer thrombo-zythärnie mit niedrig dosierter acetylsalicylsaure. Schweiz Med Wochenschr 1983;113:1622–1627.
  • Michiels JJ, Abels J, Steketee J, van Vliet HHDM, Vuzevski VD. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Int Med 1985;102:466–471.
  • Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR. From efficacy to safety: A polycythemia vera study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997;34:17–23.
  • Spivak JL. The optimal management of polycythemia vera. Br J Haematol 2002;116:243–254.
  • Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T. Efficacy and safety of low-dose aspirin in polycythemia vera: Results of the ECLAP trial. N Engl J Med 2004;350:114–124.
  • Katarsky I, Sharon R. Management of polycythemia vera with hydroxyurea. Semin Hematol 1997;34:24–28.
  • Michiels jj, Barbui T, Finazzi G, Fruchtman SM, Kutti J, Rain J-D, Silver RT, Tefferi A, Thiele J. Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG. Leuk Lymphoma 2000;36:239–253.
  • Najean Y, Rain J-D, French PVSG. Treatment of polycythemia vera: The use of hydroxyurea and pipobmman in 292 patients under the age of 65 years. Blood 1997;90: 3370–3377.
  • Silver RT. A new treatment for polycythemia vera: Recombi-nant interferon-alpha. Blood 1990;76:664–665.
  • Silver RT. Interferon-alpha 2b: A new treatment for polycythemia vera. Ann Intern Med 1993;119:1091–1092.
  • Silver RT. Interferon-alpha: Effects of long-term treatment for polycythemia vera. Semin Hematol 1997;34:40–50.
  • Silver RT. Log-term effects of the treatment of polycythemia vera with recombinant interferon-a. Cancer 2006;107: 451–458.
  • Taylor PC, Dolan G, Ng JP, et al. Efficacy of recombinant interferon-alpha in polycythemia vera: A study of 17 patients and an analysis of published data. Br J Haematol 1996;92: 55–59.
  • Elliott MA, Tefferi A. Interferon-alpha in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 1997;23:463–472.
  • Fruehauf S, Topaly J, Villalobos M, Veldwijk MR, Laufs S, Ho AD. Quantitative real-time polymerase chain reaction shows that treatment with interferon reduces the initially upregulated PRV-1 expression in polycythemia vera patients. Haemato-logica 2003;88(3):349–351.
  • Jones AV, Silver RT, Waghorn K, Curtis C, Kreil S, Zoi K, Hochhaus A, Oscier D, Metzgeroth G. Minimal molecular response in polycythemia vera patients treated with imanitib or interferon alpha. Blood 2006;107(8): 3339–3341, April 15; Epub 2005 December 13.
  • Tefferi A, Gilliland DG. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: Status report and immediate implications for disease classification and diagnosis. Mayo Chin Proc 2005;80(7):947–958.
  • Samuelsson J. A phase II trial of pegylated interferon a-2b therapy for polycythemia vera and essential thrombocythemia. Cancer 2006;106(11):2397–2405, June.
  • Kiladjian JJ, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S, Menot ML, Massonnet G, Dutel JL, Ghomari K, Rousselot P, Grange MJ, Chait Y, Vainchenker W, Parquet N, Abdelkader-Aljassem L, Bernard JF, Rain JD, Chevret S, Chomienne C, Fenaux P. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006;108(6):2037–2040, September 15; Epub 2006 May 18.
  • Wasserman LR. The management of polycythemia vera. Br J Haematol 1971;21:371–376.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.